JP2020534269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534269A5 JP2020534269A5 JP2020514936A JP2020514936A JP2020534269A5 JP 2020534269 A5 JP2020534269 A5 JP 2020534269A5 JP 2020514936 A JP2020514936 A JP 2020514936A JP 2020514936 A JP2020514936 A JP 2020514936A JP 2020534269 A5 JP2020534269 A5 JP 2020534269A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024060206A JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US62/558,510 | 2017-09-14 | ||
| PCT/US2018/050916 WO2019055677A1 (en) | 2017-09-14 | 2018-09-13 | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060206A Division JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534269A JP2020534269A (ja) | 2020-11-26 |
| JP2020534269A5 true JP2020534269A5 (https=) | 2021-10-21 |
Family
ID=65723086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514936A Pending JP2020534269A (ja) | 2017-09-14 | 2018-09-13 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子−１（ｃｌｌ−１）に結合するタンパク質 |
| JP2024060206A Pending JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060206A Pending JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200277384A1 (https=) |
| EP (1) | EP3681532A4 (https=) |
| JP (2) | JP2020534269A (https=) |
| KR (1) | KR20200051789A (https=) |
| CN (1) | CN111432832A (https=) |
| AU (1) | AU2018331412A1 (https=) |
| BR (1) | BR112020005078A2 (https=) |
| CA (1) | CA3075857A1 (https=) |
| EA (1) | EA202090718A1 (https=) |
| IL (1) | IL273206A (https=) |
| MA (1) | MA50255A (https=) |
| MX (1) | MX2020002880A (https=) |
| SG (1) | SG11202002298PA (https=) |
| WO (1) | WO2019055677A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| WO2019178364A2 (en) * | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| WO2020081841A1 (en) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| MX2022004430A (es) * | 2019-10-15 | 2022-07-19 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| MX2022013944A (es) * | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| KR20230008157A (ko) * | 2020-05-06 | 2023-01-13 | 드래곤플라이 쎄라퓨틱스, 인크. | 항체 표적화 clec12a 및 이의 사용 |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| PE20241789A1 (es) * | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN117106086A (zh) * | 2022-08-09 | 2023-11-24 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| WO2010080124A2 (en) * | 2008-12-18 | 2010-07-15 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| EP3470431A1 (en) * | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| WO2017125897A1 (en) * | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| CN120173123A (zh) * | 2017-02-27 | 2025-06-20 | 蜻蜓疗法股份有限公司 | 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白 |
-
2018
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/en not_active Ceased
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/en active Pending
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en not_active Abandoned
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt not_active Application Discontinuation
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en not_active Abandoned
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 CA CA3075857A patent/CA3075857A1/en active Pending
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Ceased
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
-
2024
- 2024-04-03 JP JP2024060206A patent/JP2024099539A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534269A5 (https=) | ||
| AU2025200204A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
| CN105051066B (zh) | 作为T细胞衔接器的双特异性IgG抗体 | |
| JP2025060941A5 (https=) | ||
| CN110551221B (zh) | 一种双特异性抗体及其制备方法与应用 | |
| Castillo et al. | Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders | |
| TWI867066B (zh) | 靶向flt3之抗體及其用途 | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| CN107406506A (zh) | 用于治疗急性髓系白血病的抗cd38抗体 | |
| TW201231066A (en) | Pan-HER antibody composition | |
| Felten et al. | Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases | |
| JP2018520101A5 (https=) | ||
| US11384146B2 (en) | BTLA-binding antibodies for modulating immune response and treating disease | |
| JP2018519263A5 (https=) | ||
| Sacchi et al. | Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab | |
| JP2024521408A (ja) | Ｃｄ２０、ｎｋｐ４６、ｃｄ１６に結合し、かつｉｌ－２にコンジュゲートされた多特異性抗体 | |
| JP2020507577A5 (https=) | ||
| JP2024529494A (ja) | 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用 | |
| JP6914283B2 (ja) | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 | |
| CN115697402A (zh) | 靶向clec12a的抗体及其用途 | |
| JPWO2019164930A5 (https=) | ||
| CN117858906A (zh) | 与cldn18.2和cd3结合的双特异性结合剂 | |
| CN116143942A (zh) | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 | |
| JP2021526845A (ja) | Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療 | |
| JP2025175307A (ja) | 逐次抗ｃｄ１９治療 |